BioNTech CEO Sahin sells 79K shares in plan

BioNTech’s CEO Ugur Sahin reports 79,000-share Rule 10b5-1 plan sales while retaining a large indirect stake via Medine GmbH.

Rhea-AI Filing Summary

BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 79,000 Ordinary Shares in open-market or private transactions on September 21–22, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. A form-level holding entry shows 39,218,111 Ordinary Shares held indirectly through Medine GmbH, of which 106,721 shares are held in trust where Medine GmbH has voting but not dispositive power; Sahin may be deemed to beneficially own the shares held by Medine GmbH.

Insider Trade Summary 10b5-1

Net Seller: 79,000 shares

Net Sell 3 txns

Insider Sahin Ugur

Role Chief Executive Officer

Sold 79,000 shs ($7.86M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	46,000	$100.7182	$4.63M
Sale	Ordinary Shares	33,000	$97.8097	$3.23M
holding	Ordinary Shares F1	--	--	--

Holdings After Transaction: Ordinary Shares — 410,209 shares (Direct); Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)

Footnotes (1)

1. F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Key Figures

Shares sold on September 22, 2026: 46,000 shares Sale price on September 22, 2026: $100.7182 per share Shares sold on September 21, 2026: 33,000 shares +5 more

8 metrics

Shares sold on September 22, 2026 46,000 shares Ordinary Shares sold in open-market or private transaction

Sale price on September 22, 2026 $100.7182 per share Ordinary Shares transaction by Ugur Sahin

Shares sold on September 21, 2026 33,000 shares Ordinary Shares sold in open-market or private transaction

Sale price on September 21, 2026 $97.8097 per share Ordinary Shares transaction by Ugur Sahin

Total shares sold in reported transactions 79,000 shares Sum of Ordinary Shares sold on September 21–22, 2026

Indirect holdings via Medine GmbH 39,218,111 shares Ordinary Shares indirectly held as of September 21, 2026

Trust-held shares with limited power 106,721 shares Shares where Medine GmbH has voting but not dispositive power

Rule 10b5-1 plan adoption date June 3, 2026 Plan under which the reported sales were executed

Key Terms

Rule 10b5-1 trading plan, Ordinary Shares, dispositive power, beneficially own

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Ordinary Shares financial

"The ordinary shares are held by Medine GmbH."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

dispositive power regulatory

"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

beneficially own regulatory

"The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH."

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BioNTech (BNTX) CEO Ugur Sahin report in this Form 4?

Ugur Sahin reported two sales totaling 79,000 Ordinary Shares of BioNTech SE on September 21–22, 2026 in open-market or private transactions, as disclosed in this Form 4.

At what prices were the BioNTech (BNTX) shares sold by Ugur Sahin?

Sahin sold 46,000 Ordinary Shares at $100.7182 per share on September 22, 2026, and 33,000 Ordinary Shares at $97.8097 per share on September 21, 2026, according to the filing.

Were Ugur Sahin’s BioNTech (BNTX) share sales made under a Rule 10b5-1 plan?

Yes. The filing states that the sales reported were effected pursuant to a Rule 10b5-1 trading plan established by Ugur Sahin on June 3, 2026.

How many BioNTech (BNTX) shares does Ugur Sahin indirectly hold after these transactions?

A holding entry shows 39,218,111 Ordinary Shares held indirectly through Medine GmbH. The filing notes that Sahin is the sole shareholder of Medine GmbH and may be deemed to beneficially own these shares.

What does the filing say about the 106,721 BioNTech (BNTX) shares held in trust?

The footnote explains that 106,721 Ordinary Shares are held for the benefit of an individual under a trust. Medine GmbH exercises voting power, but not dispositive power, over these shares while they remain in trust.

Does the Form 4 attribute the Medine GmbH BioNTech (BNTX) holdings to Ugur Sahin?

Yes. The footnote states that the Ordinary Shares are held by Medine GmbH, that Sahin is its sole shareholder, and that he may be deemed to beneficially own the Ordinary Shares held by Medine GmbH.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 05:05 PM Accepted by SEC EDGAR 09/22/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sahin Ugur

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/21/2026		S		33,000	D	$97.8097	456,209	D
Ordinary Shares	09/22/2026		S		46,000	D	$100.7182	410,209	D
Ordinary Shares								39,218,111	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Remarks:

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.

	/s/ Humza Bokhari, Attorney-in-Fact	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)